Skip to main content
NCBI home page
Nature Portfolio logoLink to Nature Portfolio
. 2022 Sep 13;28(9):1965. doi: 10.1038/s41591-022-02037-1

Publisher Correction: Plasma p-tau231 and p-tau217 as state markers of amyloid-β pathology in preclinical Alzheimer’s disease

Marta Milà-Alomà 1,2,3,4,#, Nicholas J Ashton 5,6,7,8,#, Mahnaz Shekari 1,2,3,4, Gemma Salvadó 1,2,3, Paula Ortiz-Romero 1,2, Laia Montoliu-Gaya 5, Andrea L Benedet 5,9, Thomas K Karikari 5,10, Juan Lantero-Rodriguez 5, Eugeen Vanmechelen 11, Theresa A Day 12, Armand González-Escalante 1,2, Gonzalo Sánchez-Benavides 1,2,3, Carolina Minguillon 1,2,3, Karine Fauria 1,3, José Luis Molinuevo 1, Jeffrey L Dage 12,13, Henrik Zetterberg 5,14,15,16, Juan Domingo Gispert 1,2,3,17, Marc Suárez-Calvet 1,2,3,18,✉, Kaj Blennow 5,14,✉
PMCID: PMC9499861  PMID: 36100683

Correction to: Nature Medicine 10.1038/s41591-022-01925-w, published online 11 August 2022.

In the version of this article initially published, the Acknowledgments text, now reading “M.S.C. receives funding from the European Research Council (ERC) under the European Union’s Horizon 2020 research and innovation program (grant agreement no. 948677), the Instituto de Salud Carlos III (PI19/00155), and from the ERC under the EU’s ‘la Caixa’ Foundation (ID 100010434) and from the EU’s Horizon 2020 research and innovation program under the Marie Skłodowska-Curie grant (no. 847648, LCF/BQ/PR21/11840004),” was incomplete and has now been amended in the HTML and PDF versions of the article.

Contributor Information

Marc Suárez-Calvet, Email: msuarez@barcelonabeta.org.

Kaj Blennow, Email: kaj.blennow@neuro.gu.se.

Articles from Nature Medicine are provided here courtesy of Nature Publishing Group

RESOURCES